



Veselovskaia Ana, Gamaniuc Marina Universitatea de Stat de Medicină și Farmacie "Nicolae Testemițanu", Catedra de medicină de laborator, Chișinău, Republica Moldova

Author(s), affiliation Introduction

In December 2019, a new coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in the Chinese province of Wuhan and rapidly infected hundreds of thousands of people worldwide. Infected patients mostly exhibit general signs of pneumonia (fever, dyspnea, coughing and desaturation) and a presumably significant number of infected patients are asymptomatic.

Keywords

COVID-19, liver damage, biomarkers.

Purpose

Study of literature data on biomarkers of liver damage in patients with COVID-19 infection that could provide information about liver damage.

Material and methods

A study of the literature from the PubMed database was performed. The keywords were used in the search process - "COVID-19", "liver damage", "biomarkers".

Results

Lactate dehydrogenase, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are often elevated in COVID-19 patients, indicating liver damage. Recent reports point to the fact that liver injury, by means of increased aminotransferase levels, more frequently occurred in severe COVID-19 cases compared to patients with mild symptoms.

CONSACRAT ANIVERSĂRII A 75-A DE LA FONDAREA USMF "NICOLAE TESTEMIȚANU"

Liver damage in patients with COVID-19 infection





cells.



Conclusions

Further studies are needed on the impact of SARS-CoV-2 virus on liver

Increased viral reactivation in HBV Autoimmune hepatitis flare

Hepatic injury super-added to underlying dysfunction Increased risk of decompensation in Trigger for acute over chronic liver